Clearmind Medicine Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMND research report →
Price Chart
About the company
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions.
- CEO
- Adi Zuloff-Shani
- IPO
- 2022
- Employees
- 4
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on CMND
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.08M
- P/E
- -0.07
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.09
- EV/EBITDA
- 1.11
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -87.29%
- ROIC
- -60.10%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-49,364+3.3%
- Op Income
- $-5,666,653
- Net Income
- $-3,856,627+26.6%
- EPS
- $-24.24+55.3%
- OCF Growth
- +30.0%
- FCF Growth
- +30.0%
- 52W High
- $3840.00
- 52W Low
- $5.25
- 50D MA
- $10.92
- 200D MA
- $65.26
- Beta
- -1.16
- RSI (14)
- 29
- Avg Volume
- 68.95K
No earnings-call transcripts are available for CMND yet.
- Free Float
- 74.3%
- Shares Outstanding
- 185.69K
- Float Shares
- 138.02K
of shares held by institutions
2 13F filers
Buy/sell ratio 0.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 1 ETFs
Biggest fund positions in CMND by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | HRT FINANCIAL LP | sell | 22,139 |
| Jun 15, 26 | HRT FINANCIAL LP | sell | 3,183 |
| Jun 12, 26 | HRT FINANCIAL LP | sell | 2,102 |
| Jun 10, 26 | HRT FINANCIAL LP | buy | 2,159,052 |
| Jun 11, 26 | HRT FINANCIAL LP | sell | 225,191 |
| Jun 10, 26 | HRT FINANCIAL LP | other | 0 |
| May 12, 17 | Lamadrid David | other | 857,143 |
| May 1, 17 | Lamadrid David | other | 0 |
| May 1, 17 | Lamadrid David | other | 0 |
| May 1, 17 | Lamadrid David | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CMND coverage
Recent articles, reports, and earnings notes.
No research on CMND yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CMND report →NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
thenewswire.com · Sep 23
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
globenewswire.com · Sep 23
Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio
thenewswire.com · Sep 17
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
globenewswire.com · Sep 17
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
globenewswire.com · Sep 11
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
globenewswire.com · Sep 8
Clearmind Medicine Stock Slides Friday: What's Happening?
benzinga.com · Sep 4
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
globenewswire.com · Sep 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.